Daily Newsletter

20 November 2023

Daily Newsletter

20 November 2023

Monash University team to receive funds for prostate cancer therapy

The project under Professor Gail Risbridger is one of ten developments to share $50m in NHMRC funding.

Vishnu Priyan November 20 2023

A team of researchers at Monash University in Australia will receive a $5m grant from the government for the development of CAR T cell therapy to treat prostate cancer.

Professor Gail Risbridger and the team received the National Health and Medical Research Council (NHMRC) grant.

Australian Health Minister Mark Butler stated: “We are living through a supercharged period of discovery, especially in CAR T cell therapy.

“CAR T cell therapy is an immunotherapy that promises to turn medicine on its head, by unlocking the ability of a patient’s immune system to find and destroy cancer and other disease.

“This is world-leading health research and the Albanese government is proud to fund this important work.”

Risbridger’s strategy will leverage a new integrated approach of generating CAR T cells, a range of test models and imaging tools to expedite the therapy into clinical trials. 

CAR T cell therapy is an immunotherapy that selects immune cells from the patient’s own body and provides those cells with the genetic data required to detect and kill cancer cells.

The project under Risbridger is one of ten developments to share $50m in funding through NHMRC’s synergy grants.

NHMRC CEO Professor Steve Wesselingh stated: “The synergy grant scheme supports high-performing research teams to tackle complex research questions and improve human health.

“These grants offer opportunities to foster collaboration between diverse researchers to ensure a range of skills and perspectives are brought together to solve a problem.”

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Acute Renal Failure (ARF) - Market Landscape

Only a handful of approved therapeutic drugs are currently available for the treatment of ARF, all belonging to the solute carrier family 12 member 1 inhibitor. The clinical trial space in ARF consists of almost an equal mix of commercial as well as academic sponsors, with Iran and the US emerging as the key countries for conducting Phase III trials. While the current marketed drug space for ARF has only a handful of treatment options, currently available mid-to-late-stage pipeline drugs are likely to pave the way for a new treatment approach in the future.

Newsletters by sectors


Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Vist our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.